Common antidepressant may ease long COVID’s crushing fatigue

AI justification

Clinical trial proves significant benefit for long COVID patients with accessible treatment | The clinical trial provides robust evidence of a tangible medical benefit for long COVID patients, aligning with SDG 3 (Good Health and Well-being) and UDHR Article 25 (right to health). The low-cost nature of fluvoxamine enhances accessibility, particularly for vulnerable populations. No significant negative aspects were identified in this action.